Fundamentals of Nursing Flashcards

Drugs desired therapeutic effects and it's adverse effects

A narrow index is more difficult to manage

• may require close monitoring for toxicity or adverse effects
• EX. seizure meds

A wider therapeutic index is safer and requires less monitoring

• EX is antibiotics and propranolol

biological effects that can be measured continually up to the maximum responding capacity of the biological system

• BLOOD PRESSURE
• HEART RATE

biological effects are present or not present

effects of a response that may or may not happen

• SEIZURES
• RASH

What the drug does to the body

• Ease of titration
• Therapeutic index
• A narrow therapeutic index is more difficult to manage.
• seizure medications
• A wider therapeutic index is safer and requires less monitoring.
• Like antibiotics

The movement of the drug to the bodies circulation

• Distribution
• Ability to cross blood–brain barrier
• Cytochrome P450 (CYP450) metabolism
• Renal elimination
• Dose–concentration curve
• Half-life

The movement of the drug to the body's circulation

Things to consider:

• Route of Administration
  • IV, IM, oral, sublingual, intranasal
  • ***IV fastest method of drug absorption
• Site of Administration
  • Topical- targets the site
  • Inhaler- goes straight to lungs
  • Ophthalmic- goes to the eyes
• Bioavailability
  • % of the drug that is truly absorbed/administered
  • IV- 100% vs Oral 10-90%
  • "availability of drug that is truly absorbed"
• Peak blood levels
  • highest level of drug in the body

The movement of the drug to the target organ/tissues

• Good blood supply
  • Drug distributed to areas of high blood flow first then to low blood flow areas
  • EX: Kidneys, liver first then adipose tissue

Size of molecule

• smaller molecules are better able to diffuse than larger molecules in passive diffusion

Acid & Base Environments

Protein binding

• Plasma proteins in blood
• Albumin is a major protein in the blood
• Consider pts with renal/ liver disease because proteins are produced less or excreted

Transporters

• influenced by transporters, membrane proteins that
  facilitate the movement of molecules across the cell membranes

Volume of Distribution

Blood-Brain Barrier

• very protected- impenetrable
• only lipid soluble drugs can pass

Placental Barrier

• Many drugs can pass barrier
• Low molecular weight drugs pass easier

Drugs exists in bound or unbound status

Travel when bound and cross membranes when unbound

• Drug action occurs when drug is unbound

Highly protein bound drug means that less of the drug is available

Low plasma protein (low albumin d/t decrease liver, renal fnx, malnourished, cancer pts-cells feed off body) will result in more free drug

Chemical alteration of drug to metabolites

Metabolism increase or decreases onset, duration, and toxicity of the drug

The breakdown of the drug in the liver

First pass IS FOR ORAL DRUGS

• Concentration of the medication function that is reduced before it reaches circulation
• Occurs in the liver or gut
• first pass may break down most function of drug so may need to consider another route of administration

Half life

• Time it takes for 50 % of the drug to be eliminated

It is a major drug metabolizing enzyme

Organized into numbered families

Enzymes can slow or increase drug metabolism

Concurrent administration w/ inhibitor or inducer can alter metabolism of medication

Pro-drugs-- need to go through metabolism to become an active form of drug

• Age
• Genetics
• Pregnancy
• Diet
• ETOH
• Liver disease
• Environment
• Timing
• Drug Interactions

Removal of drug from body to organs of elimination

***The drug moving to the potty

• Kidney
• GI
• Lungs- ETOH, Ketosis
• Skin- Sweat
• Saliva
• Mammary Glands- via breast milk

Kidney function

Age

• Infants/Older adults @ risk for ADR bc renal function (immature or decreased)

Hydration

Cardiac Output

Read graph from left to right to represent increase dose concentration

• Dose- response curve shows the relationship between drug dose and magnitude on effect
• Dose below the curve do not produce a pharmacological response
• Dose above the curve do not produce additional pharmacological response
  • May have unwanted side effects = toxicity

Potency: the amount of the drug needed to produce a biological effect

Efficacy: The maximum effect a drug can produce

Intrinsic activity: ability to produce a response once the drug is attached to the receptors

Ratio of the dose producing undesired effects

Minimum effective concentration (MEC): level below therapeutic effects will not occur

Min toxic concentration (MTC): level above which toxic effects occur

Therapeutic Index: ratio of MTC to MEC

Define the patient problem

Specify the therapeutic objective

Collaborate with the patient

Choose the treatment

Educate the patient

Monitor effectiveness

Assess the patient

Develop differential diagnosis

Use diagnostic test to confirm

Cure the disease?

Help relieve S/S

Long term prevention

Replace what is needed- Insulin, Vitamin D

make the patient comfortable with palliative therapy

The World Health Organization recommends including the patient in developing the therapeutic objectives of drug therapy.

• first determine what the appropriate therapy would be using evidence-based guidelines
• second, individualize the drug choice for the specific patient
  • consider pharmacokinetics & -dyamics
  • Determine the cost of the drug
    • When writing a prescription, discuss whether patient has ability to pay for prescription.

• Patient education should be at the 5th or 6th grade level.
• Include in education:
  • Purpose of medication
  • Instructions for administration
  • Adverse drug reactions (ADRs)
• Poor adherence contributes to worsening disease, hospital admissions, and death.

***purpose of insulin is to control BG, how to administer insulin, SE of hypoglycemia. IF do not take medication- can contribute to worsen diabetes, hospital readmission, death

• Passive monitoring: Passive monitoring includes educating the patient on the expected outcome of the drug therapy and instructing the patient to contact the provider if the treatment is not effective or if adverse drug effects occur
  • EX antibiotics
• Active monitoring: Follow-up laboratory tests or monitoring to measure therapeutic effectiveness.
  • EX seizure medications, anticoags

• therapeutic impact of a drug is reviewed in the literature and observed in
  the individual patient
• Evidence for therapeutic impact
  
  • Clinical trials
  • Clinical practice guidelines
  • Systematic reviews
• Randomized controlled trials
  
  • Extrapolate with caution because tend to use healthy individuals when in reality, patients are complex
    

• The safety profile of a drug is taken into consideration and weighed against
  other factors when prescribing.
• Safety is initially determined in clinical trials and is outlined in the precautions and contraindications in the drug
  monograph.
• Safety may vary with the population.
  • Tetragons
  • Liver or renal disease
  • Drug allergies
• The U.S. Food and Drug Administration (FDA) collects information on
  and monitors the safety of drugs via postmarketing surveillance by the
  MedWatch program
• The FDA issues a “Public Health Advisory” when there is drug safety information that needs to be conveyed to patients or caregivers.

• Cost to patient
• High drug cost = patient may decrease adherence
• Ask about prescription drug coverage
• Consider $4 retail pharmacy lists
• Cost to society
• Thoughtful prescribing considers cost to healthcare system

Previous experience w/ ADRs

• ADRs can be a significant factor in nonadherence
• Renal pts more at risk for ADRs

Health Beliefs

Current Drug Therapy

• Drug interactions
• If a patient is on a complex medication regimen, consultation with a pharmacist or PharmD who has access to drug interaction software is warranted for patient safety.

Age

• either the very young or the very old

Pregnant

• Ease of prescribing or monitoring
• Formularies
• Nurse practitioners need to be familiar with the formularies they are allowed to prescribe.
• Personal formulary: Each provider develops a small list of drugs they are comfortable prescribing.

• Pharmaceutical promotion
• May influence prescribing
• Changes in prescribing recommendations
• When guidelines change, providers may need to be coached or reeducated regarding appropriate prescribing.

• Pharmacogenomics is the branch of pharmacology that deals with the influence of genetic variations on drug response in patients by correlating gene expression with a drug’s efficacy or toxicity.

• In other words, drugs and drug combinations are optimized for each individual’s unique genetic makeup.

Genetic makeup contribute to many variations in pharmacokinetics

Most drugs are metabolized through cytochrome P450 enzyme system

various factors contribute to specific observable pharmacodynamics differences

• CYP450 enzymes are involved in about 75% of drug metabolism and bioactivation in the liver
• Some CYPs metabolize only one (or a very few) drug(s), whereas others may metabolize multiple drugs
• The CYP3A subfamily is responsible for over 50% of drug metabolism
• Race, gender, environmental factors, and drugs may alter the gene expression of individual CYP450 families and subfamilies
• 40% of Asians display drug polymorphism

• What are the clinical implications when substrates inhibit CYP450 enzymes?
• An inhibitor may decrease the metabolism of substrates and generally lead to increased drug effect.
• What are the clinical implications when substrates induce CYP450 enzymes
  • An inducer may increase the metabolism of substrates and generally lead to decreased drug effect.

• Poor metabolizers
  • break down meds slowly
  • experience side effects at the standard dose
• Intermediate metabolizers
  • may have too much medication on board at a standard dose, causing side effects
• Extensive metabolizers
  • normal rate of metabolism
• Ultra-rapid metabolizers
  • meds are rapidly broken down
  • meds may be removed from the system before providing any symptom relief

• Pharmacoeconomics defined
• Provides a framework for evaluating drug treatments in terms of comparing one treatment with another
• Pharmacoeconomics studies
• Generic drugs

• Generic drugs may or may not be less expensive.
• Pharmacy coverage may determine whether a generic drug is used.
• Tiered benefit
  • Many benefit plans have a two- or three-tiered benefit, in which the patient pays a greater co-payment for brand-name drugs than for generic equivalent prescriptions
• Lower co-pay for generic drugs
• Retail prescription drug programs.

• 69% of prescriptions filled with generic drugs
• Prescriber influenced by:
• Innovator company
• Payer
• Patient
• Innovator companies support for health care

• FDA regulates and sets standards for bioequivalence
  • Be bioequivalent (an equal rate and extent of drug absorbed in the bloodstream)

• FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations is:
• Available online
• Searched by active ingredient
• Searched by proprietary name
• Updated daily

• Prescribing generic vs brand-name drugs
• Pharmacist may substitute a less expensive drug that is therapeutic equivalent
• “Dispense as written”
• Patients may switch due to costs and prescription benefit.
• Retail drug programs
• Walmart, Target, Kroger, Sam’s Club
• $4 for a 30-day supply of common generic drugs for Metoformin vs 70% brand name